NHLRC1 Antibody, FITC conjugated

Shipped with Ice Packs
In Stock

Description

Applications in Research

ApplicationDetails
ImmunofluorescenceDetects NHLRC1 in human heart and brain tissues (recommended dilution: 1:20–1:200) .
Western BlotIdentifies NHLRC1 at 45–47 kDa in L02 cell lysates (1:500–1:1,000 dilution) .
ELISAQuantifies NHLRC1 in human serum samples using biotin- or FITC-conjugated variants .
Disease ResearchUsed to study Lafora disease (EPM2), linked to NHLRC1 mutations (e.g., C46Y, D146N) .

Validation and Specificity

  • Specificity: Confirmed via immunoblotting and immunohistochemistry in human, mouse, and rat samples .

  • Cross-Reactivity: No reported cross-reactivity with unrelated proteins .

  • Key Findings:

    • NHLRC1-FITC antibodies localize to cytoplasmic aggregates in Lafora disease models .

    • Mutations (e.g., L261P) disrupt NHLRC1’s ability to degrade glycogen synthase, leading to toxic polyglucosan accumulation .

Research Findings and Clinical Relevance

  • Lafora Disease: NHLRC1-FITC antibodies help identify pathogenic mutations (e.g., D146N) that impair protein degradation, contributing to epilepsy and neurodegeneration .

  • Glycogen Regulation: NHLRC1 ubiquitinates PPP1R3C/PTG, reducing glycogen accumulation in cellular models .

Limitations and Considerations

  • Light Sensitivity: FITC fluorescence degrades under prolonged light exposure .

  • pH Sensitivity: FITC’s fluorescence intensity decreases in acidic environments (pH < 6.0) .

  • Sodium Azide Interference: Must be removed prior to conjugation to prevent reaction with FITC .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Typically, we can ship the products within 1-3 business days after receiving your order. The delivery timeframe may vary based on your chosen purchasing method and location. Please consult your local distributors for specific delivery time estimates.
Synonyms
E3 ubiquitin-protein ligase NHLRC1 (EC 2.3.2.27) (Malin) (NHL repeat-containing protein 1) (RING-type E3 ubiquitin transferase NHLRC1), NHLRC1, EPM2B
Target Names
Uniprot No.

Target Background

Function
NHLRC1, also known as Malin, is an E3 ubiquitin-protein ligase. It plays a critical role in protein degradation and cellular homeostasis. Collaborating with the phosphatase EPM2A/laforin, it appears to be involved in the clearance of toxic polyglucosan and protein aggregates through multiple pathways. In a complex with EPM2A/laforin and HSP70, NHLRC1 effectively reduces the cellular toxicity of misfolded proteins by facilitating their degradation through the ubiquitin-proteasome system (UPS). NHLRC1 ubiquitinates the glycogen-targeting protein phosphatase subunits PPP1R3C/PTG and PPP1R3D in a laforin-dependent manner, directing them for proteasome-dependent degradation. This process ultimately reduces glycogen accumulation. NHLRC1 also polyubiquitinates EPM2A/laforin and ubiquitinates AGL, targeting them for proteasome-dependent degradation. Additionally, NHLRC1 promotes protein degradation through the macroautophagy pathway, independent of the proteasome.
Gene References Into Functions
  1. NHLRC1 promotes its own degradation through auto-ubiquitination. It preferentially degrades the phosphatase-inactive laforin monomer. PMID: 26648032
  2. The laforin/malin complex interacts with and ubiquitinates both PKM1 and PKM2. PMID: 26493215
  3. Lafora disease proteins laforin and malin negatively regulate the HIPK2-p53 cell death pathway. PMID: 26102034
  4. Research has shown that NHLRC1 mutations are detected in some cases of Mild Lafora disease patients. PMID: 25270369
  5. In the absence of a functional laforin-malin complex assembled on polyglucosan bodies, polyglucosan degradation does not occur. PMID: 24068615
  6. NHLRC1 regulates the recruitment of mRNA-decapping enzyme 1A (Dcp1a) to processing bodies. PMID: 23131811
  7. NHLRC1 forms a functional complex with laforin. This complex promotes the ubiquitination of proteins involved in glycogen metabolism, and misregulation of pathways involved in this process results in Lafora body formation. (Review) PMID: 22815132
  8. This study identified NHLRC1 gene mutations leading to Lafora disease in six Turkish families. PMID: 22047982
  9. Research indicates that NHLRC1 regulates the Wnt signaling pathway through the degradation of dishevelled2, suggesting possible deregulation of Wnt signaling in Lafora disease. PMID: 22223637
  10. Mutations in the NHL repeat containing 1 (NHLRC1) gene have been described in association with a milder clinical course and later age of death in an adolescent patient. PMID: 21555062
  11. Laforin and malin are defective in Lafora disease (LD), a neurodegenerative disorder associated with epileptic seizures. PMID: 21652633
  12. malin(C46Y), malin(P69A), malin(D146N), and malin(L261P) mutants failed to downregulate the level of R5/PTG, a regulatory subunit of protein phosphatase 1 involved in glycogen synthesis. PMID: 21505799
  13. NHLRC1 negatively regulates neuronatin, and its loss of function in Lafora disease results in increased accumulation of neuronatin. PMID: 21742036
  14. NHLRC1 is related to TRIM32 at both the phylogenetic and functional level. PMID: 21798009
  15. A study described several novel mutations of EPM2A and NHLRC1 and provided additional data to the genetic epidemiology of Lafora disease (LD). It emphasized the high mutation rate in patients with classical LD as well as the high negativity rate of skin biopsy. PMID: 20738377
  16. These results suggest that the modification introduced by the laforin-malin complex could affect the subcellular distribution of AMPK beta subunits. PMID: 20534808
  17. The co-chaperone carboxyl terminus of the Hsc70-interacting protein (CHIP) stabilizes NHLRC1 by modulating the activity of Hsp70. PMID: 19892702
  18. Laforin and NHLRC1 colocalize to the ER, suggesting they operate in a related pathway protecting against polyglucosan accumulation and epilepsy. PMID: 12958597
  19. Genetic allelic heterogeneity is present in Lafora disease associated with mutations in EPM2B. Patients with mutations in EPM2A and EPM2B express similar clinical manifestations. PMID: 15781812
  20. NHLRC1 is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. PMID: 15930137
  21. NHLRC1 is an E3 ubiquitin ligase that binds glycogen synthase. PMID: 16115820
  22. Patients with NHLRC1 mutations have a slower rate of disease progression than those with EPM2A mutations. PMID: 16950819
  23. Defects in NHLRC1 may lead to increased levels of misfolded and/or target proteins, which may eventually affect the physiological processes of the neuron, potentially serving as the primary trigger in the physiopathology of Lafora disease. PMID: 17337485
  24. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase complex pathway. PMID: 18029386
  25. NHLRC1 ubiquitinates PTG in a laforin-dependent manner, both in vivo and in vitro, and targets PTG for proteasome-dependent degradation. These findings suggest an additional mechanism, involving laforin and NHLRC1, in regulating glycogen metabolism. PMID: 18070875
  26. The authors identified 14 Lafora epilepsy patients in the genetic isolate of tribal Oman. The study demonstrates that in this homogeneous environment and gene pool, the same mutation, EPM2B-c.468-469delAG, results in highly uniform ages of onset and death. PMID: 18263761
  27. Results suggest that the altered subcellular localization of mutant proteins of the EPM2A and NHLRC1 genes could be one of the molecular bases of the Lafora disease phenotype. PMID: 18311786
  28. Laforin and NHLRC1 interact with misfolded proteins and promote their degradation through the ubiquitin-proteasome system. PMID: 19036738
  29. Phosphorylation of R5/PTG at Ser-8 by AMPK accelerates its laforin/malin-dependent ubiquitination and subsequent proteasomal degradation, leading to a decrease in its glycogenic activity. PMID: 19171932
  30. Results describe a novel homozygous single-nucleotide variant in the NHLRC1 gene in a Malian consanguineous family. PMID: 19322595
  31. Laforin and NHLRC1 play a role in protecting cells from ER-stress, likely contributing to the elimination of unfolded proteins. PMID: 19529779
  32. Meta-analysis of gene-disease association. (HuGE Navigator) PMID: 19267391
  33. The phosphatase laforin acts as a scaffold that allows NHLRC1 to ubiquitinate protein targeting to glycogen (PTG). These results suggest an additional mechanism, involving laforin and NHLRC1, in regulating glycogen metabolism. PMID: 18070875

Show More

Hide All

Database Links

HGNC: 21576

OMIM: 254780

KEGG: hsa:378884

STRING: 9606.ENSP00000345464

UniGene: Hs.348351

Involvement In Disease
Epilepsy, progressive myoclonic 2 (EPM2)
Subcellular Location
Endoplasmic reticulum. Nucleus. Note=Localizes at the endoplasmic reticulum and, to a lesser extent, in the nucleus.
Tissue Specificity
Expressed in brain, cerebellum, spinal cord, medulla, heart, liver, skeletal muscle and pancreas.

Q&A

What is NHLRC1 and why is it significant in neurological research?

NHLRC1 (NHL repeat-containing protein 1), also known as Malin or EPM2B, is a single subunit E3 ubiquitin ligase that contains a RING-type zinc finger domain and six NHL-repeat domains . This protein is of significant research interest because:

  • It forms a functional complex with laforin (encoded by EPM2A) to regulate glycogen synthesis

  • It suppresses cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS)

  • Mutations in NHLRC1 are causative for Lafora disease (progressive myoclonic epilepsy type 2), a fatal autosomal recessive neurodegenerative disorder

The study of NHLRC1 provides critical insights into protein quality control mechanisms and the pathogenesis of neurodegenerative diseases characterized by protein aggregation.

How does FITC conjugation to NHLRC1 antibodies occur at the molecular level?

FITC (Fluorescein Isothiocyanate) conjugation to NHLRC1 antibodies involves a chemical reaction between the isothiocyanate group of FITC and primary amines (typically lysine residues) on the antibody. The process follows these steps:

  • The reactive fluorescein molecule (FITC) is dissolved in an organic solvent like DMSO immediately before use due to its instability

  • The antibody is prepared in a carbonate or borate buffer at pH 8.0-9.5 to ensure that lysine ε-amino groups are deprotonated for optimal reactivity

  • The FITC solution is slowly added to the antibody solution while gently mixing to achieve the desired FITC:antibody molar ratio (typically aiming for 3-6 FITC molecules per antibody)

  • The reaction proceeds at room temperature in the dark for 1-2 hours

  • Unconjugated FITC is removed by gel filtration or dialysis against phosphate-buffered saline (PBS)

This conjugation technique creates a stable thiourea bond between FITC and the antibody, enabling fluorescent detection of NHLRC1 while maintaining the antibody's binding specificity.

What are the optimal storage conditions for maintaining FITC-conjugated NHLRC1 antibody stability?

For maximum stability and performance of FITC-conjugated NHLRC1 antibodies:

  • Store at -20°C in small aliquots to avoid repeated freeze-thaw cycles

  • Keep in storage buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • Protect from continuous light exposure, which can gradually reduce fluorescence intensity

  • Maintain in the dark during all storage and handling steps

  • Avoid contamination by using sterile technique during aliquoting

Some commercial FITC-conjugated antibody preparations remain stable for up to one year when properly stored at -20°C . When preparing to use the antibody, thaw a single aliquot on ice and keep protected from light until use in the experimental procedure.

What are the recommended dilutions and applications for FITC-conjugated NHLRC1 antibodies?

FITC-conjugated NHLRC1 antibodies can be utilized across several applications with the following recommended dilutions:

ApplicationRecommended DilutionBuffer CompositionNotes
Immunofluorescence1:20-1:200PBS with 10% FBSEmpirically determine optimal dilution for specific cell types
Flow Cytometry1:50-1:200PBS with 1% BSALower dilution may be needed for weak expression
Immunohistochemistry1:20-1:200PBS with 10% FBSRequires antigen retrieval with TE buffer pH 9.0 or citrate buffer pH 6.0
Western Blot1:500-1:1000TBS with 5% milk/BSARequires secondary detection with HRP/AP-conjugated secondary antibody

For NHLRC1 detection in neuronal tissues or cells expressing NHLRC1 at low levels, starting with more concentrated antibody dilutions (1:20-1:50) is advisable. For all applications, include proper controls and perform titration experiments to determine the optimal signal-to-noise ratio in your specific experimental system .

How can I optimize an immunofluorescence protocol specifically for detecting NHLRC1 using FITC-conjugated antibodies?

An optimized immunofluorescence protocol for NHLRC1 detection with FITC-conjugated antibodies requires careful attention to several parameters:

  • Cell preparation and fixation:

    • Grow cells on chamber slides or coverslips to 70-80% confluence

    • Fix with 4% paraformaldehyde for 20 minutes at room temperature

    • Permeabilize with 0.5% Triton X-100 for 5 minutes

  • Blocking and antibody incubation:

    • Block with PBS containing 10% fetal bovine serum for 20-30 minutes to reduce non-specific binding

    • Dilute FITC-conjugated NHLRC1 antibody (1:50-1:200) in blocking solution

    • Incubate cells with antibody solution for 1 hour at room temperature in the dark

  • Washing and mounting:

    • Wash cells 2-3 times for 5 minutes each with PBS to remove unbound antibody

    • Mount with anti-fade mounting medium containing DAPI for nuclear counterstaining

    • Seal edges with nail polish to prevent drying

  • Visualization:

    • Observe using a fluorescence microscope equipped with appropriate FITC filter set (excitation ~490 nm, emission ~525 nm)

    • Capture images using exposure settings that avoid photobleaching

For improved specificity when studying NHLRC1's interaction with the ubiquitin-proteasome system, co-staining with antibodies against known interaction partners like laforin (EPM2A) using different fluorophores (e.g., Texas Red) can provide valuable colocalization data .

Why might I observe high background or non-specific staining when using FITC-conjugated NHLRC1 antibodies?

High background or non-specific staining with FITC-conjugated NHLRC1 antibodies can result from several factors:

ProblemPotential CausesSolution Strategies
High fluorescent backgroundExcessive FITC labeling (over-conjugation)Use antibodies with optimal FITC:antibody ratio (3-6 FITC molecules per antibody)
Insufficient blockingIncrease blocking time or use stronger blocking agents (5% BSA, 10% normal serum)
Antibody concentration too highTitrate the antibody to determine optimal dilution; use more dilute antibody preparations
Non-specific bindingCross-reactivity with other proteinsValidate antibody specificity using positive and negative controls
Insufficient washingIncrease number and duration of washing steps with PBS containing 0.05% Tween-20
Cell autofluorescenceInclude unstained controls; consider using Sudan Black B (0.1%) to quench autofluorescence

Research has shown that FITC-conjugated antibodies with higher labeling indices tend to be more sensitive but are also more prone to non-specific staining . For NHLRC1 detection specifically, the optimal FITC:antibody ratio should be determined empirically by comparing several conjugates with different labeling densities in your experimental system.

How can I verify the specificity of my FITC-conjugated NHLRC1 antibody?

To confirm the specificity of your FITC-conjugated NHLRC1 antibody, implement these validation approaches:

  • Positive and negative control samples:

    • Use cell lines with known NHLRC1 expression (e.g., L02 cells)

    • Include cells where NHLRC1 is absent or knocked down (siRNA)

    • Examine tissues with differential NHLRC1 expression (e.g., brain versus non-neural tissues)

  • Competitive inhibition:

    • Pre-incubate the antibody with excess recombinant NHLRC1 protein before staining

    • Signal should be significantly reduced or eliminated if the antibody is specific

  • Dual validation with unconjugated antibody:

    • Compare staining pattern between FITC-conjugated and unconjugated NHLRC1 antibody

    • Use Western blot analysis to verify the detection of a single band at the expected molecular weight (42-47 kDa)

  • Epitope mapping validation:

    • For NHLRC1 specifically, confirm recognition of the correct domain (RING domain or NHL repeats)

    • Check reactivity against recombinant fragments representing different domains of NHLRC1

  • Cross-validation with alternate detection methods:

    • Compare immunofluorescence results with immunohistochemistry or Western blot data

    • Use multiple antibodies targeting different epitopes of NHLRC1

Remember that proper validation should demonstrate not only presence of signal in positive samples but also appropriate subcellular localization (NHLRC1 localizes primarily to the endoplasmic reticulum and to a lesser extent in the nucleus) .

How does FITC conjugation affect the binding kinetics and sensitivity of NHLRC1 antibody detection?

FITC conjugation can significantly impact NHLRC1 antibody performance through several mechanisms:

  • Effect on binding affinity:

    • Research demonstrates a negative correlation between FITC-labeling index and binding affinity for target antigens

    • Each FITC molecule conjugated to lysine residues alters the antibody's charge profile and potentially its conformational stability

    • Over-labeling (>6 FITC molecules per antibody) can substantially reduce binding affinity by modifying lysines in or near the antigen-binding region

  • Sensitivity considerations:

    • Moderately labeled antibodies (3-4 FITC molecules per antibody) often provide optimal balance between brightness and binding affinity

    • Higher labeling ratios increase fluorescence intensity but may compromise specificity and increase background

    • For detecting low-abundance NHLRC1 expression, signal amplification methods may be preferable to excessive FITC labeling

  • Quantitative implications:

    • For quantitative applications (e.g., measuring NHLRC1 expression levels), consistent FITC:antibody ratios between batches is critical

    • Standardize using fluorescent beads or calibration standards to normalize between experiments

    • Consider using secondary antibody detection systems when precise quantitation is required

When selecting FITC-conjugated NHLRC1 antibodies for research, evaluate technical documentation regarding the FITC:protein ratio and validate performance empirically in your experimental system. For detecting subtle changes in NHLRC1 expression or localization, antibodies with moderate FITC labeling typically provide the best balance of sensitivity and specificity .

What methodological considerations are important when studying NHLRC1 mutations using FITC-conjugated antibodies?

When investigating NHLRC1 mutations associated with Lafora disease using FITC-conjugated antibodies, researchers should consider several methodological factors:

  • Epitope accessibility in mutated proteins:

    • Confirm that your FITC-conjugated antibody's epitope is not directly affected by the mutation of interest

    • NHLRC1 mutations in the RING domain (C46Y, P69A) or NHL domains (D146N, L261P) may alter protein conformation and epitope accessibility

    • Use antibodies targeting regions distant from mutation sites or multiple antibodies recognizing different epitopes

  • Expression level variations:

    • Mutations may affect NHLRC1 protein stability or expression levels

    • Standardize detection protocols with appropriate loading controls

    • Consider complementary techniques like Western blotting to quantify expression differences

  • Subcellular localization changes:

    • NHLRC1 mutations can alter subcellular trafficking and localization

    • Use confocal microscopy with z-stack imaging to accurately determine 3D localization patterns

    • Co-stain with organelle markers (ER, nucleus) to detect mislocalization of mutant proteins

  • Functional interaction studies:

    • For studying how mutations affect NHLRC1's interaction with binding partners like laforin:

      • Perform co-immunoprecipitation followed by immunofluorescence

      • Use dual-color labeling with FITC-conjugated NHLRC1 antibody and Texas Red-conjugated antibodies against interaction partners

      • Employ proximity ligation assays for higher sensitivity in detecting protein-protein interactions

  • Analysis of polyglucosan inclusions:

    • When studying Lafora bodies, combine FITC-conjugated NHLRC1 antibody staining with periodic acid-Schiff (PAS) staining

    • Optimize fixation and permeabilization to preserve both protein epitopes and glycogen-like aggregates

For researching specific NHLRC1 mutations like C46Y, P69A, D146N and L261P, cell models expressing these variants should be carefully validated to ensure that the mutant proteins are recognized by your FITC-conjugated antibody with similar efficiency as the wild-type protein .

How can FITC-conjugated NHLRC1 antibodies be effectively employed in co-localization studies with other proteins in the ubiquitin-proteasome pathway?

To effectively use FITC-conjugated NHLRC1 antibodies in co-localization studies with ubiquitin-proteasome pathway components:

  • Multi-channel fluorescence imaging setup:

    • Pair FITC (green fluorescence, Ex/Em: 495/519 nm) with spectrally distinct fluorophores like Texas Red or Cy3 (red) and Cy5 (far-red) for multi-protein detection

    • Ensure your microscope has appropriate filter sets to minimize spectral overlap

    • For complex co-localization studies, use confocal microscopy with sequential scanning to prevent bleed-through

  • Sample preparation for optimal co-localization analysis:

    • Fix cells using paraformaldehyde (4%) to preserve protein interactions and spatial relationships

    • For membrane proteins, avoid harsh permeabilization; use 0.1-0.2% Triton X-100 or 0.1% saponin

    • For co-staining of NHLRC1 with ubiquitin or proteasome components:

      • FITC-conjugated NHLRC1 antibody (1:100)

      • Texas Red-conjugated anti-ubiquitin or anti-proteasome antibodies (1:200)

  • Validated co-localization protocols for NHLRC1 interactions:

    • For NHLRC1-laforin interactions:

      • Co-stain with FITC-conjugated NHLRC1 and Texas Red-conjugated laforin antibodies

      • Focus on areas with Lafora body formation in neuronal models

    • For NHLRC1-Dvl2 (Wnt signaling) co-localization:

      • Use FITC-conjugated anti-ubiquitin antibody together with Texas Red-conjugated anti-Dvl2 in cells expressing NHLRC1

      • Examine localization changes upon proteasome inhibition (e.g., MG132 treatment)

  • Quantitative co-localization analysis:

    • Calculate Pearson's correlation coefficient or Manders' overlap coefficient

    • Use JACoP plugin in ImageJ or similar software for unbiased analysis

    • Control for random co-localization using protein pairs known not to interact

  • Confirming functional associations:

    • Complement imaging with biochemical approaches (co-immunoprecipitation, proximity ligation)

    • For NHLRC1's E3 ligase activity assessment, monitor ubiquitination status of target proteins in parallel with co-localization studies

When studying NHLRC1's role in targeting proteins for degradation, time-course experiments combining FITC-conjugated NHLRC1 antibody with proteasome markers can reveal dynamic changes in co-localization during the protein degradation process .

What are the critical experimental controls needed when using FITC-conjugated NHLRC1 antibodies for detecting Lafora bodies in clinical samples?

When using FITC-conjugated NHLRC1 antibodies to detect Lafora bodies in clinical samples, implement these essential controls:

  • Antibody specificity controls:

    • Isotype control: Use FITC-conjugated non-specific immunoglobulin (same isotype as NHLRC1 antibody)

    • Absorption control: Pre-incubate FITC-conjugated NHLRC1 antibody with excess recombinant NHLRC1 protein

    • Secondary antibody-only control (if using indirect detection method)

  • Tissue-specific controls:

    • Positive control: Include known Lafora disease tissue sections with confirmed Lafora bodies

    • Negative control: Include age-matched normal tissue sections

    • For brain tissue: Use antigen retrieval with TE buffer pH 9.0 (or citrate buffer pH 6.0 as alternative)

  • Autofluorescence mitigation:

    • Include unstained tissue section to assess natural autofluorescence

    • Use Sudan Black B (0.1-0.3%) treatment to quench tissue autofluorescence

    • Employ spectral unmixing if confocal microscope with spectral detection is available

  • Validation with conventional staining:

    • Perform parallel PAS (Periodic Acid-Schiff) staining on adjacent sections

    • Compare FITC-NHLRC1 immunolabeling with PAS-positive inclusions

    • For definitive confirmation, consider dual PAS-immunofluorescence labeling

  • Inter-laboratory standardization:

    • Document acquisition parameters (exposure time, gain, filter settings)

    • Include fluorescent intensity calibration standards

    • Process and image reference samples alongside test samples

For clinical diagnosis of Lafora disease, immunofluorescence with FITC-conjugated NHLRC1 antibodies should be used as a complementary technique to genetic testing for NHLRC1 mutations, as some mutations may affect antibody recognition or protein expression levels . Lafora bodies should show positive staining for NHLRC1 and typically appear as cytoplasmic inclusions in neurons, but can also be found in liver, muscle, and heart tissue samples .

How can FITC-conjugated NHLRC1 antibodies be utilized in studying the relationship between NHLRC1 and glycogen metabolism disorders?

FITC-conjugated NHLRC1 antibodies offer valuable tools for investigating NHLRC1's role in glycogen metabolism and related disorders:

  • Visualization of glycogen-associated protein complexes:

    • Use FITC-conjugated NHLRC1 antibodies (1:50-1:100) alongside antibodies against:

      • Laforin (EPM2A) - NHLRC1's functional partner in glycogen regulation

      • R5/PTG - regulatory subunit of protein phosphatase 1 involved in glycogen synthesis

      • Glycogen synthase (GS) - key enzyme in glycogen formation

    • Perform z-stack confocal imaging to visualize 3D relationships between these proteins and glycogen particles

  • Characterization of polyglucosan bodies:

    • Combine FITC-NHLRC1 immunofluorescence with glycogen staining methods:

      • Periodic Acid-Schiff (PAS) staining modified for fluorescence microscopy

      • Specific glycogen-binding protein probes

    • This dual approach allows correlation between NHLRC1 localization and abnormal glycogen structures

  • Monitoring dynamic changes in glycogen metabolism:

    • Design time-course experiments using cell models with fluorescently-tagged NHLRC1 and glycogen metabolism enzymes

    • Apply glucose challenges or glycogen metabolism inhibitors to observe redistribution of NHLRC1 relative to glycogen particles

    • Quantify changes in co-localization coefficients over time

  • Analyzing mutation-specific effects on glycogen regulation:

    • Compare wild-type and mutant NHLRC1 localization relative to glycogen accumulation

    • Data from Lafora disease patients showed that mutations (C46Y, P69A, D146N, and L261P) prevent the laforin-malin complex from downregulating R5/PTG-induced glycogen synthesis

    • Quantify differences in glycogen levels and NHLRC1 association across mutations using fluorescence intensity measurements

  • Cross-species comparison in model systems:

    • Validate FITC-conjugated NHLRC1 antibody reactivity across relevant animal models

    • Compare glycogen metabolism phenotypes and NHLRC1 distribution in mouse, rat, and human samples

    • Document species-specific differences in NHLRC1 association with glycogen particles

These approaches can help elucidate the molecular mechanisms through which NHLRC1 mutations lead to the abnormal glycogen accumulation characteristic of Lafora disease, potentially identifying targets for therapeutic intervention .

What considerations are important when using FITC-conjugated NHLRC1 antibodies for high-resolution microscopy techniques?

When employing FITC-conjugated NHLRC1 antibodies for advanced microscopy techniques, researchers should address these technical considerations:

  • Super-resolution microscopy optimization:

    • For STED (Stimulated Emission Depletion) microscopy:

      • FITC is not ideal due to photobleaching; consider converting to more photostable fluorophores like Alexa Fluor 488

      • Use mounting media with anti-fade agents formulated for super-resolution

      • Optimize depletion laser power to balance resolution and signal preservation

    • For STORM/PALM techniques:

      • FITC's photoswitching properties are suboptimal; consider immunolabeling with primary anti-NHLRC1 followed by secondary antibodies conjugated to superior photoswitching dyes

      • Use oxygen-scavenging buffer systems to enhance photostability

      • Ensure high labeling density for accurate reconstruction

  • Sample preparation refinements:

    • For optimal NHLRC1 visualization at nanoscale resolution:

      • Use thinner sections (70-100 nm) for improved signal-to-noise ratio

      • Apply gentler fixation protocols (2% PFA instead of 4%) to preserve epitope accessibility

      • Consider membrane extraction techniques to better visualize association with cytoskeletal elements and organelles

  • Multi-color high-resolution imaging approaches:

    • When combining FITC-conjugated NHLRC1 with other fluorophores:

      • Select fluorophores with minimal spectral overlap

      • For 3-4 color imaging, use sequential acquisition with careful channel alignment

      • Consider chromatic aberration correction for accurate co-localization analysis at nanoscale resolution

  • Quantitative aspects for nanoscale analysis:

    • For accurate quantification of NHLRC1 distribution and clustering:

      • Use appropriate density-based clustering algorithms

      • Apply calibration standards to account for different detection efficiencies between fluorophores

      • Consider molecular counting approaches to estimate absolute numbers of NHLRC1 molecules in complexes

  • Live-cell super-resolution considerations:

    • For studying dynamic behavior of NHLRC1:

      • FITC photobleaching limits extended imaging; consider generating cells expressing NHLRC1 fused to more photostable fluorescent proteins

      • Use reduced illumination intensity with longer acquisition times

      • Apply denoising algorithms optimized for low-signal conditions

By addressing these technical aspects, researchers can leverage high-resolution microscopy to elucidate previously unresolvable details of NHLRC1's interaction with binding partners and its role in protein quality control pathways at the nanoscale level.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.